Eyenovia Inc (EYEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eyenovia Inc (EYEN) has a cash flow conversion efficiency ratio of 0.457x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.44 Million) by net assets ($-9.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Eyenovia Inc to measure how many days the company can operate on defensive assets alone.
Eyenovia Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Eyenovia Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Eyenovia Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eyenovia Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Heron Therapeuti
NASDAQ:HRTX
|
-0.169x |
|
Ekinops SA
PA:EKI
|
0.018x |
|
Radhika Jeweltech Limited
NSE:RADHIKAJWE
|
0.003x |
|
GAM Holding AG
SW:GAM
|
-0.865x |
|
Sab Zenzele Kabili Holdings
JSE:SZK
|
0.020x |
|
MMP Industries Limited
NSE:MMP
|
0.079x |
|
Kirloskar Electric Company Limited
NSE:KECL
|
-7.328x |
|
Dongsin Engineering & Construction
KQ:025950
|
-0.056x |
Annual Cash Flow Conversion Efficiency for Eyenovia Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Eyenovia Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Eyenovia Inc (EYEN) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-13.10 Million | $-30.12 Million | 2.300x | +186.83% |
| 2023-12-31 | $9.00 Million | $-23.84 Million | -2.649x | -81.83% |
| 2022-12-31 | $17.23 Million | $-25.11 Million | -1.457x | -42.82% |
| 2021-12-31 | $20.47 Million | $-20.87 Million | -1.020x | -144.49% |
| 2020-12-31 | $15.30 Million | $-6.38 Million | -0.417x | +74.11% |
| 2019-12-31 | $11.74 Million | $-18.92 Million | -1.611x | -107.41% |
| 2018-12-31 | $16.88 Million | $-13.11 Million | -0.777x | +16.40% |
| 2017-12-31 | $5.09 Million | $-4.73 Million | -0.929x | +12.70% |
| 2016-12-31 | $3.01 Million | $-3.20 Million | -1.065x | +33.35% |
| 2015-12-31 | $2.40 Million | $-3.83 Million | -1.597x | -- |
About Eyenovia Inc
Eyenovia, Inc., an ophthalmic technology company, engages in development and commercialization of ophthalmic solutions in the United States. The company offers Optejet, a topical ophthalmic medication dispensing platform services. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vi… Read more